Keyphrases
Multiple Sclerosis
100%
Disease Severity
100%
Metabolic Signature
100%
Expanded Disability Status Scale
75%
Disability
50%
Metabolic Profiling
50%
Amino Acids
50%
Serum Samples
50%
Lipid Acids
50%
Lysophosphatidylethanolamine
50%
Principal Coordinate Analysis (PCoA)
25%
Clinical Change
25%
Disease-based
25%
Liquid Chromatography-tandem Mass Spectrometry (LC-MS/MS)
25%
Clinical Relapse
25%
Series Analysis
25%
Severe Disease
25%
Stable Disease
25%
Active Disease
25%
Partial Least Squares Discriminant Analysis (PLS-DA)
25%
Disease Biomarker
25%
Tryptophan
25%
Lysophosphatidylcholine
25%
Eicosapentaenoic Acid
25%
Glutamic Acid
25%
Relapse-free
25%
Hydrocortisone
25%
Ultra-high Performance Liquid Chromatography (UHPLC)
25%
Parametric Method
25%
Sphingomyelin
25%
Severe Course
25%
Longitudinal Cohort
25%
Hydroxyoctadecadienoic Acid
25%
Medicine and Dentistry
Multiple Sclerosis
100%
Metabolomics
100%
Disease Severity
100%
Expanded Disability Status Scale
60%
Diseases
40%
Amino Acid
40%
Glutamic Acid
20%
Biological Marker
20%
Hydrocortisone
20%
Mass Spectrum
20%
Partial Least Squares Regression
20%
Time Series Analysis
20%
Icosapentaenoic Acid
20%
Principal Component Analysis
20%
Discriminant Analysis
20%
Tryptophan
20%
Ultra Performance Liquid Chromatography
20%
Lysophosphatidylcholine
20%
Metabolite
20%
Sphingomyelin
20%
Neuroscience
Multiple Sclerosis
100%
Expanded Disability Status Scale
75%
Lysophosphatidylethanolamine
50%
Amino Acid
50%
Cortisol
25%
Time Series Analysis
25%
Sphingomyelin
25%
Glutamic Acid
25%
Mass Spectrometry
25%
Icosapentaenoic Acid
25%
Tryptophan
25%
Lysophosphatidylcholine
25%
Biochemistry, Genetics and Molecular Biology
Metabolomics
100%
Lipid
40%
Amino Acids
40%
Lysophosphatidylethanolamine
40%
Ultra High Performance Liquid Chromatography
20%
Principal Component Analysis
20%
Eicosapentaenoic Acid
20%
Metabolite
20%
Mass Spectrometry
20%
Cortisol
20%
Glutamic Acid
20%
Sphingomyelin
20%
Tryptophan
20%
Lysophosphatidylcholine
20%